Event Details

Join amfAR and the O’Neill Institute for National and Global Health Law for a briefing:

Long-Acting HIV Treatment and Prevention Are Coming:
Preparing for Potential Game Changers

Monday, July 16, 2018 | 12:00 – 1:30 PM
Georgetown University Law Center
Eric E. Hotung International Law Building, Room 2001 (Faculty Dining)

Lunch will be served
Invitation-Only
Please RSVP

This briefing will feature:

Scientific Update

Dr. Carl W. Dieffenbach
Director, Division of AIDS
National Institute Allergy and Infectious Diseases
National Institutes of Health

Release of amfAR/O'Neill Institute Policy Briefs

Jeffrey S. Crowley and Sean Bland
O’Neill Institute for National and Global Health Law

Panel Discussion

Greg Millett, amfAR (Moderator)
K. Rivet Amico, University of Michigan School of Public Health
Lindsey Dawson, Henry J. Kaiser Family Foundation
Tim Horn, Treatment Action Group
Vanessa Johnson, Ribbon Consulting Group

***
Innovative products for treating and preventing HIV infection are under development. Sometimes called long-acting agents, such products may take different forms ranging from injections to implants to oral medications. If determined to be safe and effective, what could make these new therapies transformative is that they would not require daily dosing. Some products may require monthly dosing and others may require therapy only a few times a year. Taking an idea and turning it into a desirable, effective, affordable, and accessible product is a long and difficult process.

To support needed education and policy dialogue, amfAR and the O’Neill Institute are releasing four briefs:

Overview that summarizes the need for and major policy issues related to extending access to new products;
Food and Drug Administration (FDA) review and approval process, including special considerations for long-acting products for HIV treatment and prevention;
Payer landscape, exploring the laws and policies that shape pharmaceutical access in public and private insurance programs and how payers may respond to innovative new products; and
Defining the market, addressing issues such as adherence to non-daily products, consumer and provider acceptability, and cost-effectiveness.